The law, our Articles of Association, internal codes and guidelines make up Mentis Cura's corporate governance framework and determines the duties and conduct of the various bodies within the company. Sound corporate governance practices support sustainable growth and builds trust between the Company's various stakeholders. We are committed to continously develop and strengthen our governance framework and aim to comply with industry best-practices for corporate governance.
The 5 largest shareholders as of 31 March 2019
North Murray AS
Rondane Holding AS
Abelsnes Invest AS
Extraordinary General Meeting Mentis Cura ehf
13 February 2020
Extraordinary General Meeting Mentis Cura AS
5 February 2020
Annual General Meeting Mentis Cura ehf
27 May 2019
Annual General Meeting Mentis Cura AS
13 May 2019
The Board of Directors is the highest decision making body within Mentis Cura between Annual General Meetings.
The Board appoints the group CEO. Claes Watndal has served as CEO since 2018.
The Board of Directors is appointed on an annual basis at the Annual General Meeting. The current members of the Board were elected at an Extraordinary General Meeting on 5 February 2020.
Gert has more than 20 years of senior executive and CEO experience, as well as having served on multiple Boards as a director or chairman.
He served as CEO of Alpharma, Inc., a NYSE-listed pharmaceutical company, and worked for McKinsey & Co. both in Scandinavia and in New York. Gert was CEO of NetCom ASA, bringing it to profitability four years after commercial launch and leaving it at as Norway’s 9th largest company in terms of market cap. He was Executive Vice President of Hafslund Nycomed pharmaceuticals and energy group, and CEO of Nycomed Imaging. Gert established Herkules Private Equity in 2002 where he serves as founding partner and Chairman.
Gert holds a degree in economics and statistics from the University of Oslo, and an MBA and an MIA from Columbia University in New York.
Joachim is a serial entrepreneur who has led companies through all phases from raising seed funding util successful exit. He is the founder of Stay.com and the first web hotel booking service in Scandinavia. In recent years Joachim has lead and structuresd the process of raising funding into several spin-off companies from research institutes in Norway.
Joachim holds a PhD in Pharmacology from the University of Oslo.
Audun is the managing director of Techstars Energy Accelerator and an investor that has served on the board of various companies.
He is a former management consultant at PriceWaterhouseCoopers in Oslo and Washington D.C. and was a visiting lecturer at the University of Oslo and Norwegian School of Management within the fields of entrepreneurship and innovation.
Audun holds an M.Sc. in International Marketing and Strategy from the Norwegian School of Management (BI).
Carl is a former manager of the financial analysis department at DNB, Norway’s largest financial services group.
He has 23 years of experience as an investor in companies in a wide range of areas including real estate, bonds and stocks.
Carl holds an MBA from the University of Wisconsin.
Friðrik is the CFO of the Icelandic New Business Venture Fund. He has a diverse background as an executive in IT, retail and media, as well as chairing and serving on the board of various companies, organizations and funds. He has extensive experience in the reorganization of companies, mergers and acquisitions as well as management consulting.
Friðrik has a Cand. Oecon. degree from the University of Iceland, a Masters of economics and an MBA from Virginia Tech.
Helena is a medical doctor and published author. She is a specialist doctor in psychiatry and has many years of clinical experience from internal medicine and psychiatry as well as serving on the board of various companies.
Helena is an M.D. and a Ph.D. from the Sahlgrenska Academy at the University of Gothenburg.
Jan has over two decades of executive leadership roles from pharmaceutical and medtech companies. He is former president of GE Healthcare Norway and General Manager at GE Healthcare Pharma Japan, and has served on the board of various Norwegian and internatiuonal companies, including two Japanese. Jan is currently an industrial life science and healthcare advisor to Investinor, an investment fund owned by the Norwegian government.
Jan holds an M.Sc. in physiology from the University of Oslo.